A PYMNTS Company

US: NY Attorney General nabs victory in Actavis challenge

By  |  December 16, 2014

A federal judge issued an injunction Monday that prevents pharmaceutical conglomerate Actavis from pulling an older Alzheimer’s treatment from pharmacy shelves and replacing it with a newer version of the drug, a tactic known as product-hopping, say reports.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The decision came in response to a lawsuit filed by New York Attorney General Eric Schneiderman, who argued that Forest Laboratories, owned by Actavis, was simply looking to protect profits by forcing customers to switch to the newer version of the drug by prematurely ending the sale of the older version. In doing so, Actavis releases its brand-name product before a cheaper, generic version can come onto the market and compete following the expiration of the brand name drug’s patent.

    Reports say the older drug’s patent is set to expire in July, and the newer version’s patent expires in 2025.

    Actavis will appeal the ruling, which followed a preliminary injunction announced last week.

    Full content: Wall Street Journal

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.